Page 26 - Zai Lab News Today

The Legal Singularity: How Artificial Intelligence Can Make Law Radically Better was out July 18

Zai Lab Ltd. (ZLAB) shares are progressing more than 5 percent on Tuesday morning trade. Yesterday, the company had reported positive data from ADHERE study of VYVGART Hytrulo in patients with chronic inflammatory demyelinating polyneuropathy.

NEW YORK, July 16, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating...

Study met primary endpoint ; VYVGART® Hytrulo demonstrated 61% reduction in risk of relapse versus placebo IgG autoantibodies shown to play significant role in underlying CIDP disease biology...

Study met primary endpoint (p=0.000039); VYVGART® Hytrulo demonstrated 61% reduction (HR: 0.39 95% CI: 0.25; 0.61) in risk of relapse versus placebo IgG...

Argenx SE (NASDAQ: ARGX) reported topline results from the ADHERE study evaluating Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with chronic inflammatory 

U.S. stock futures traded mixed this morning on Monday. Here are some big stocks recording losses in today’s pre-market trading session.

By Chris Wack Argenx shares were up 25% to $474.87 in premarket trading after the company said it and Zai Lab saw positive topline results from their study...

By Chris Wack Argenx shares were up 30% to $492.01 Monday after the immunology company said it saw positive topline results from its study with biopharmaceutical company Zai Lab evaluating...

Gainers ProMIS Neurosciences, Inc. (NASDAQ: PMN) shares jumped 126.6% to $6.37. ProMIS showcased preclinical data at the Alzheimer's Association International Conference 2023 on computationally-derived antibody and vaccine from Alzheimer's pipeline.